FORUM Pharmaceuticals (Formerly Known As EnVivo Pharmaceuticals, Inc.)
225 Second Avenue
Waltham
Massachusetts
02451
United States
Tel: 617-225-4250
Fax: 617-225-4267
Website: http://www.forumpharma.com/
Email: media@forumpharma.com
52 articles about FORUM Pharmaceuticals (Formerly Known As EnVivo Pharmaceuticals, Inc.)
-
Former XTuit Pharmaceuticals Chief Executive Officer Deborah Dunsire has been appointed head of Denmark-based H. Lundbeck A/S.
-
Checkmate Notches $27 Million and Taps Ex-FORUM Pharma Exec as COO
6/19/2017
-
Former Millennium and FORUM Pharma CEO Resurfaces to Helm Massachusetts Biotech XTuit
3/9/2017
-
In Light of Two Major Failed Trials, FORUM Pharma Closes Its Doors This Week
6/29/2016
-
FORUM Pharma CEO Quits Amid Layoffs and a Possible Company Shutdown
5/27/2016
-
Bay State's FORUM Pharma Lays Off 89 After Two Failed Clinical Trials
3/28/2016
-
FORUM Pharma Announces Appointment Of George Parker As Chief Human Resources Officer And Expansion Of Management Team
12/2/2015
-
FORUM Pharma Announces Removal Of Partial Clinical Hold On Phase III Encenicline Program For Cognitive Impairment In Schizophrenia
11/11/2015
-
FORUM Pharma Halts Clinical Trials for Alzheimer’s and Schizophrenia Drug
9/17/2015
-
FORUM Pharma Announces Publication Of Encenicline Phase II Clinical Trial Results For Cognitive Impairment In Schizophrenia
7/15/2015
-
FORUM Pharma Snags Fast Track Status for Encenicline to Treat Cognitive Impairment in Schizophrenia
6/22/2015
-
FORUM Pharma Announces Presentations At Upcoming Industry And Investor Conferences
6/10/2015
-
FORUM Pharma Consolidates Operations in Anticipation of New Growth
5/19/2015
-
FORUM Pharmaceuticals To Participate In Needham & Company’s 14th Annual Healthcare Conference
4/8/2015
-
FORUM Pharmaceuticals To Participate In Suntrust Robinson Humphrey 2015 Biotechnology And Pharmaceutical Orphan Drug Day
2/18/2015
-
FORUM Pharmaceuticals To Present At Leerink Global Healthcare Conference
2/11/2015
-
FORUM Pharmaceuticals Initiates Phase 2a Clinical Trial Of FRM-0334 In Frontotemporal Dementia With GRN Mutation
2/10/2015
-
FORUM Pharmaceuticals Presents FRM-0334 Studies At 9th International Conference On Frontotemporal Dementias
10/29/2014
-
FORUM Pharmaceuticals Appoints Christine Boisclair As Vice President, Regulatory Affairs
7/9/2014
-
FORUM Pharmaceuticals Appoints Todd Shegog As Chief Financial Officer
4/22/2014